

Date: 14th January, 2026

To,
The Deputy Manager
(Department of Corporate Services)
BSE Limited
P. J. Towers Dalal Street,
Fort, Mumbai- 400001

Sub: Intimation Under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Ref: Scrip Code: 512600
Security Id: ASTALLTD

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), and in continuance of our earlier intimation dated 10th October, 2025 wherein we have informed about allotment of 3,04,58,187 equity shares pursuant to share swap to acquire the 100% stake in Sriven Pharmachem India Private Limited, we wish to inform you that the Board of Directors of the Company has approved the allotment of 30,425,632 equity shares to discharge the Consideration for Acquisition of Sriven Pharmachem India Private Limited ("SPIPL"/ "Target Company").


The details as required under SEBI Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 are enclosed herewith as "Annexure A"


The above intimation is given to you for your record, kindly take the note of the same.

Thanking You,

Yours faithfully,

For Astal Laboratories Limited


Mahendra Kumar
(Company Secretary & Compliance officer)
Membership No.: A71224



ANNEXURE-1

Detailed disclosure as required under Regulation 30 of SEBI (LODR) Regulations, 2015 read with SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024:

<p>a) Name of the target entity, details in brief such as size, turnover etc.;</p>	<p>i) Name of the Target Company: Sriven Pharmachem India Private Limited ('SPIPL'/'Target Company')</p> <p>ii) Details of the Target Company: Sriven Pharmachem India Private Limited is engaged in Developing and producing specified high profile Drug Intermediates and Specialty Chemicals.</p> <p>iii) April- March 2025 Turnover: Rs. 1,027,009,061.00/- Net Profit: Rs. 6,991,744.00/-</p> <p>iv) Authorised Share Capital of the Target Company: Rs. 31,00,00,000/- divided into 3,10,00,000 Equity Shares of Rs. 10/- each.</p> <p>v) Paid-up share capital of the Target Company: Rs. 30,45,81,870/- divided into 3,04,58,187 Equity Shares of Rs. 10/- each.</p>
<p>b) Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";</p>	<p>The proposed acquisition would fall within Related Party Transaction.</p> <p><i>Note: Mr. Sudheer Karna Kankanala, the Director of Astal Laboratories Limited ("the Company"), being a shareholder of Sriven Pharmachem India Private Limited is an Allottee.</i></p>
<p>c) Industry to which the entity being acquired belongs;</p>	<p>Pharmaceutical Industry</p>

mahesh



d) Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The acquisition is of strategic nature and will help Astal Laboratories Limited to expand its products offering. The acquisition aligns with Astal Laboratories Limited's long-term vision of becoming a fully integrated pharmaceutical manufacturing company. It will deliver both immediate and sustained benefits through scale, synergy, and diversification, thereby contributing to improved operational strength, profitability, and shareholder value.
e) Brief details of any governmental or regulatory approvals required for the acquisition;	No
g) Nature of consideration - whether cash consideration or share swap and details of the same;	<p>The consideration for the acquisition of equity shares of SPIPL (the "Target Company") is discharged through cash and share swap at a ratio of 1:1 (i.e. 1 equity share of the Company to be issued and allotted against 1 equity share held by the shareholders of SPIPL), as detailed below:</p> <p>Share Swap (Non-Cash Consideration): The Company shall issue and allot 3,04,25,632 equity shares on a preferential basis to the shareholders of SPIPL towards the acquisition of 3,04,25,632 equity shares.</p> <p>Cash Consideration: The Company has paid Rs. 29,62,505.00/- to Ms. Niharika Bansal as Consideration for 32555 equity shares held in Sriven Pharmachem India Private Limited (SPIPL) at Rs. 91/- per Shares.</p> <p><i>Note: Ms. Niharika Bansal holder of 32,555 equity shares of SPIPL, sold 100 equity shares of the Company on July 17, 2025. This sale occurred within 90 trading days preceding the relevant date, violating Regulation 159(1)(c) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("SEBI ICDR Regulations"). As a result, Ms. Niharika Bansal disqualified from receiving shares under the preferential allotment so the Company acquired her shares in cash.</i></p>
h) Cost of acquisition or the price at which the shares are acquired;	Rs. 277,16,95,017/-.
i) Percentage of shareholding /control acquired and / or number of shares acquired;	Astal Laboratories Limited ('the Company') has acquired 100% Equity shares of the Target Company. Astal Laboratories Limited has become Holding Company of the Target Company upon acquisition of shares of the Target Company.
j) Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation,	<p>i) Line of Business: Manufacturing of active pharmaceutical ingredients (APIs) and intermediates.</p> <p>ii) Date of Incorporation: 5th March, 2015</p>

mahesh



history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<p>iii) Turnover of last 3 years:</p> <p>April- March 2023: Rs. 35,84,82,600.00/-</p> <p>April- March 2024: Rs. 1,007,591,448.00/-</p> <p>April- March 2025: Rs. 1,027,009,061.00/-</p> <p>iv) Profit of last 3 years:</p> <p>April- March 2023: Rs. 1,19,96,816.00/-</p> <p>April- March 2024: Rs. 49,129,976.00/-</p> <p>April- March 2025: Rs. 6,991,744.00/-</p> <p>v) Country in which the acquired entity has presence: India</p>
---	--

For Astal Laboratories Limited



Mahendra Kumar
(Company Secretary & Compliance Officer)
Membership No.: A71224

